118 related articles for article (PubMed ID: 9233098)
1. Update on carcinoid syndrome.
Melnyk DL
AANA J; 1997 Jun; 65(3):265-70. PubMed ID: 9233098
[TBL] [Abstract][Full Text] [Related]
2. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
3. Carcinoid syndrome.
Zambrzycki JK; Elliott CG
Nurse Anesth; 1993 Dec; 4(4):198-201. PubMed ID: 7907889
[TBL] [Abstract][Full Text] [Related]
4. [Update on the anesthetic management of patients with malignant carcinoid syndrome].
Rodríguez-Cosmen C; Trillo Urrutia L; Pacreu Terradas S; Comps Vicente O; Escolano Villén F
Rev Esp Anestesiol Reanim; 2005 May; 52(5):291-4. PubMed ID: 15968907
[TBL] [Abstract][Full Text] [Related]
5. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients.
Massimino K; Harrskog O; Pommier S; Pommier R
J Surg Oncol; 2013 Jun; 107(8):842-6. PubMed ID: 23592524
[TBL] [Abstract][Full Text] [Related]
6. Carcinoid tumor and intravenous octreotide infusion during labor and delivery.
Le BT; Bharadwaj S; Malinow AM
Int J Obstet Anesth; 2009 Apr; 18(2):182-5. PubMed ID: 19200714
[TBL] [Abstract][Full Text] [Related]
7. Octreotide and ketoconazole for persistent ectopic ACTH Cushing's disease due to mediastinal carcinoid.
Parthiban A; Sundaram DS; Reddy DJ; Girinath MR; Prabhakaran R; Chidambaranathan N
J Assoc Physicians India; 1995 Feb; 43(2):140. PubMed ID: 9282686
[No Abstract] [Full Text] [Related]
8. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
[TBL] [Abstract][Full Text] [Related]
9. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
Schran HF; Hager DF
Pancreas; 2008 Oct; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
[No Abstract] [Full Text] [Related]
10. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
[TBL] [Abstract][Full Text] [Related]
11. [Carcinoid tumors].
Tóth M; Prónai L; Németh AM; Tulassay Z
Orv Hetil; 2002 May; 143(19 Suppl):1087-92. PubMed ID: 12063867
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis.
Condron ME; Pommier SJ; Pommier RF
Surgery; 2016 Jan; 159(1):358-65. PubMed ID: 26603846
[TBL] [Abstract][Full Text] [Related]
13. Octreotide therapy in carcinoid disease.
Bax ND; Woods HF; Batchelor A; Jennings M
Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
[TBL] [Abstract][Full Text] [Related]
14. [The treatment of carcinoid of the small intestine with octreotide and alpha-interferon. A call for participation in a randomized study].
Ahrén B
Dtsch Med Wochenschr; 1996 May; 121(22):744-5. PubMed ID: 8646989
[No Abstract] [Full Text] [Related]
15. Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
Ammann M; Kinney MAO; Gudmundsdottir H; Santol J; Thiels CA; Warner SG; Truty MJ; Kendrick ML; Smoot RL; Anderson AL; Halfdanarson TR; Nagorney DM; Starlinger PP
Ann Surg Oncol; 2024 Jun; 31(6):3976-3977. PubMed ID: 38619707
[No Abstract] [Full Text] [Related]
16. Carcinoid heart disease: current understanding and future directions.
Patel C; Mathur M; Escarcega RO; Bove AA
Am Heart J; 2014 Jun; 167(6):789-95. PubMed ID: 24890526
[TBL] [Abstract][Full Text] [Related]
17. [Management of digestive system carcinoid tumors and carcinoid syndrome].
Mondragón Sánchez RJ; Castillero Pinilla C; Saldívar Moreno C; Oñate Ocaña LF; Ruiz Molina JM; Aiello Crocifoglio V
Rev Gastroenterol Mex; 1998; 63(4):204-10. PubMed ID: 10319670
[TBL] [Abstract][Full Text] [Related]
18. Primary ovarian carcinoid tumors: effective management of a rare and challenging condition.
Tsikouras P; Dimitraki M; Zervoudis S; Manav B; Liberis A; Galazios G; VON Tempelhoff GF
Minerva Chir; 2016 Jun; 71(3):214-5. PubMed ID: 27246876
[No Abstract] [Full Text] [Related]
19. Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome.
Majeed F; Porter TR; Tarantolo S; Duhachek-Stapelman A; Xie F; Elhendy A
Eur J Echocardiogr; 2007 Oct; 8(5):386-9. PubMed ID: 17011239
[TBL] [Abstract][Full Text] [Related]
20. Treatment with octreotide to suppress corticotropin secretion by a carcinoid tumour.
Tirovola EB; Malpas JS
J R Soc Med; 2005 Nov; 98(11):516. PubMed ID: 16260804
[No Abstract] [Full Text] [Related]
[Next] [New Search]
